Table 1. Comparison of Demographics and Clinical, Laboratory and Echocardiographic Features of Patients Examined in the Retrospective Study According to Whether or Not a CHF Patient Was Treated With Sacubitril/Valsartan.
| Patients treated with sacubitril/valsartan (n = 44) | Patients treated with conventional therapy (without sacubitril/valsartan) (n = 88) | P-value | |
|---|---|---|---|
| Baseline demographics | |||
| Age (years, mean ± SD) | 76 ± 5.5 | 75 ± 7.5 | 0.4341 |
| Male sex, n (%) | 31 (70.5%) | 60 (68.2%) | 0.9470 |
| BMI on admission (kg/m2, mean ± SD) | 28.2 ± 6.87 | 27.2 ± 5 | 0.3427 |
| Heart rate at the first visit (beats/min, mean ± SD) | 90 ± 19 | 85 ± 20 | 0.1711 |
| Heart rate after 6 months (beats/min, mean ± SD) | 64 ± 18 | 80 ± 20 | < 0.0001 |
| SBP at the first visit (mm Hg, mean ± SD) | 115 ± 26 | 125 ± 30 | 0.0617 |
| SBP after 6 months (mm Hg, mean ± SD) | 110 ± 21 | 115 ± 18 | 0.1574 |
| Comorbidities | |||
| Ischemic etiology of HF, n (%) | 20 (45.4%) | 40 (45.4%) | 0.8529 |
| Valvular etiology of HF, n (%) | 7 (15.9%) | 15 (17%) | 0.9342 |
| CMP-induced HF, n (%) | 12 (27.2%) | 27 (30.6%) | 0.8396 |
| Other cause of HF, n (%) | 5 (11.3%) | 6 (6.8%) | 0.5179 |
| Atrial fibrillation, n (%) | 22 (50%) | 22 (25%) | 0.0074 |
| CABG, n (%) | 10 (22.7%) | 25 (34%) | 0.2550 |
| History of hypertension, n (%) | 25 (56.8%) | 46 (52.2%) | 0.7576 |
| DM on insulin, n (%) | 10 (22.7%) | 25 (28.4%) | 0.6255 |
| COPD, n (%) | 5 (11.3%) | 11 (12.5%) | 1.0000 |
| ICD, n (%) | 4 (9%) | 9 (10.2%) | 1.0000 |
| NYHA class IV at baseline, n (%) | 1 (2.2%) | 6 (6.8%) | 0.4234 |
| Hematochemical variables | |||
| NT-proBNP at the first visit (pg/mL, mean ± SD) | 800.84 ± 123 | 756.22 ± 129 | 0.0594 |
| NT-proBNP after 6 months (pg/mL, mean ± SD) | 290.5 ± 90.1 | 591.47 ± 213.81 | < 0.0001 |
| Serum creatinine (mL/dL, mean ± SD) | 1.46 ± 0.55 | 1.6 ± 0.4 | 0.0981 |
| Serum Na+ at the first visit (mEq/L, mean ± SD) | 136 ± 1.55 | 137 ± 2.5 | 0.0166 |
| Serum Na+ after 6 months (mEq/L, mean ± SD) | 138.5 ± 10 | 138.4 ± 8.6 | 0.9526 |
| Serum K+ at the first visit (mEq/L, mean ± SD) | 4.5 ± 0.6 | 4.7 ± 0.9 | 0.1851 |
| Serum K+ after 6 months (mEq/L, mean ± SD) | 4.8 ± 0.65 | 4.1 ± 0.85 | < 0.0001 |
| Echocardiographic data at the first visit | |||
| LVEF (%, mean ± SD) | 39.71 ± 4.78 | 38 ± 5.44 | 0,0790 |
| LVESD (mm, mean ± SD) | 58 ± 10 | 59 ± 14 | 0.6733 |
| E/A ratio (mean ± SD) | 3 ± 1.25 | 3.4 ± 1.35 | 0.1026 |
| Deceleration time (ms, mean ± SD) | 136 ± 22 | 145 ± 25 | 0.0362 |
CHF: chronic heart failure; SD: standard deviation; BMI: body mass index; SBP: systolic blood pressure; CMP: cardiomyopathy; CABG: coronary artery bypass graft; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; ICD: implantable cardioverter defibrillator; NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter.